Jason Gerberry
Stock Analyst at B of A Securities
(3.52)
# 770
Out of 4,827 analysts
160
Total ratings
53.98%
Success rate
1.77%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $20 → $22 | $18.03 | +22.02% | 14 | May 8, 2025 | |
| PCVX Vaxcyte | Maintains: Buy | $157 → $137 | $32.52 | +321.28% | 9 | Apr 1, 2025 | |
| IMVT Immunovant | Maintains: Buy | $38 → $33 | $14.45 | +128.37% | 5 | Mar 20, 2025 | |
| VTRS Viatris | Maintains: Underperform | $11 → $10 | $9.25 | +8.17% | 3 | Feb 28, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $143 → $167 | $109.73 | +52.20% | 5 | Feb 11, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Buy | $30 | $22.51 | +33.27% | 2 | Jan 9, 2025 | |
| EXEL Exelixis | Downgrades: Neutral | $35 → $39 | $36.87 | +5.78% | 2 | Dec 17, 2024 | |
| BLUE bluebird bio | Downgrades: Neutral | $60 → $10 | $3.74 | +167.38% | 8 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Buy | $84 → $100 | $55.85 | +79.07% | 4 | Nov 6, 2024 | |
| BHVN Biohaven | Maintains: Buy | $52 → $62 | $20.45 | +203.18% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $2.88 | +733.33% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $0.68 | +343.85% | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $68 | $32.93 | +106.50% | 5 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $18.84 | +6.16% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $25.47 | +21.71% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $0.09 | +11,552.54% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $30.55 | -5.07% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $13.22 | +179.88% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $36.00 | +55.56% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $33.79 | -11.22% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $63 | $24.95 | +152.51% | 1 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $98.51 | +120.28% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $4 → $2 | $0.32 | +522.28% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $760.29 | -34.24% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.20 | +650.00% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $9.03 | +177.01% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.71 | +192.40% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $4.79 | +463.67% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $0.99 | +1,918.77% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $10 | $0.40 | +2,426.53% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $185.84 | -48.88% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $47.15 | +27.25% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $22.91 | +61.50% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $78.10 | +15.24% | 11 | Oct 17, 2019 |
Teva Pharmaceutical Industries
May 8, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $18.03
Upside: +22.02%
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $32.52
Upside: +321.28%
Immunovant
Mar 20, 2025
Maintains: Buy
Price Target: $38 → $33
Current: $14.45
Upside: +128.37%
Viatris
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $9.25
Upside: +8.17%
Axsome Therapeutics
Feb 11, 2025
Maintains: Buy
Price Target: $143 → $167
Current: $109.73
Upside: +52.20%
Catalyst Pharmaceuticals
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $22.51
Upside: +33.27%
Exelixis
Dec 17, 2024
Downgrades: Neutral
Price Target: $35 → $39
Current: $36.87
Upside: +5.78%
bluebird bio
Nov 15, 2024
Downgrades: Neutral
Price Target: $60 → $10
Current: $3.74
Upside: +167.38%
Arcellx
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $55.85
Upside: +79.07%
Biohaven
Sep 24, 2024
Maintains: Buy
Price Target: $52 → $62
Current: $20.45
Upside: +203.18%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $2.88
Upside: +733.33%
Sep 4, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.68
Upside: +343.85%
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $32.93
Upside: +106.50%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $18.84
Upside: +6.16%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $25.47
Upside: +21.71%
Mar 25, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $0.09
Upside: +11,552.54%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $30.55
Upside: -5.07%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $13.22
Upside: +179.88%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $36.00
Upside: +55.56%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $33.79
Upside: -11.22%
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $24.95
Upside: +152.51%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $98.51
Upside: +120.28%
Aug 8, 2023
Downgrades: Underperform
Price Target: $4 → $2
Current: $0.32
Upside: +522.28%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $760.29
Upside: -34.24%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.20
Upside: +650.00%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $9.03
Upside: +177.01%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.71
Upside: +192.40%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $4.79
Upside: +463.67%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $0.99
Upside: +1,918.77%
Jul 15, 2020
Downgrades: Neutral
Price Target: $17 → $10
Current: $0.40
Upside: +2,426.53%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $185.84
Upside: -48.88%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $47.15
Upside: +27.25%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $22.91
Upside: +61.50%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $78.10
Upside: +15.24%